Pricing and reimbursement

The market access of an out-patient medicinal product requires in practice that a product is reimbursable through health insurance. The processes of price and reimbursement applications have a growing significance for the success of a pharmaceutical company. In an optimal situation, a new medicinal product is available for patients who need it, in as fast and extensive manner as possible, and at a competitive price.

The basic reimbursement status can be applied directly after receiving the marketing authorization and the special reimbursement status can be applied once the basic reimbursement status has been granted for the medicinal product. The special reimbursement status can be granted, however, only provided that the disease is listed in the Government Decree and that there is sufficient use experience concerning the product. The reimbursement status and the reasonable wholesale price as the basis for the reimbursement must be renewed at regular intervals. Conditional reimbursement has provided a new opportunity for the faster implementation of new innovative medicinal products reimbursed through health insurance. 

A successful application process requires high-quality documentation of the therapeutic and economic value of the product, knowledge of the Health Insurance Act and a tactic eye in different phases of the application process.

 

Our pricing and reimbursement services: 

  • Strategic and tactic counselling in the different phases of the application process
  • Basic and special reimbursement applications of a new active substance/medicinal product
  • Renewal and extension applications for basic and special reimbursement
  • Applications concerning a new strength, package size and dosage form
  • Risk-sharing models related to conditional reimbursement and counselling

 

We are more than happy to tell you more!

Ritva Suominen
Sr. Market Access Manager
P&R Lead

Contact us

Our Pricing and Reimbursement Experts:

Ritva Suominen
Sr. Market Access Manager
P&R Lead

Ritva Suominen

Sr. Market Access Manager
P&R Lead
M.Sc. (Pharm.)

+358 40 042 0715 LinkedIn

Ritva joined Medaffcon’s team in March 2018. Before this, she worked almost six years at Farenta in corresponding tasks, providing pharmaceutical companies with strategic consultation and expert assistance related to Market Access functions. In addition, Ritva holds more than 20 years of experience in the pharmaceutical industry, where she has worked as a Market Access Manager at Sanofi (12 years), as a Regulatory Affairs Manager at Bayer and as a Researcher in Pharmaceutical Product Development at Orion.

In the pharmaceutical industry, Ritva is interested in Market Access issues particularly due to their diversity and societal impact. “Market Access is a great lookout spot to observe the development of new innovative medicinal treatment, aiming to improve patients’ treatment in its entirety. I consider it important to increase cooperation between different actors in the pharmaceutical industry and to find such new solution models that make effective treatment optimally available for patients without raising the society’s costs unreasonably. “


Jarmo Hahl
Managing Director

Jarmo Hahl

Managing Director
M.Sc. (Economics)

+358 40 139 4001 LinkedIn

Jarmo joined Medaffcon as a partner and CEO in 2010, having previously worked in various expert and management positions in pharma companies for eight years. Jarmo has a degree in economics and before entering the pharmaceutical industry he held an office at the Turku School of Economics and also worked as a research fellow at Turku University Hospital.

Jarmo has strong expertise in new health technology innovations and how the demands and expectations of authorities, markets and customers are matched. He also brings to Medaffcon extensive experience in health economics and its applications in research and commercialization, as well as a broad understanding of the ever-changing operating environment. “From the access point of view, the Finnish health technology market is constantly becoming more demanding and therefore also more attractive from my point of view. On the other hand, increasing demands to demonstrate the effectiveness and cost-effectiveness of healthcare are broadening the scope and opportunities for Medaffcon to be involved in the development of healthcare as a whole.”


Heini Honkanen
Health Economist

Heini Honkanen

Health Economist
M.Sc. (Health Economics)

+358 44 326 4477 LinkedIn

Heini joined Medaffcon’s Market Access team in May 2018. Heini has graduated in Health Economics at the University of Eastern Finland, and her master’s thesis discusses risk-sharing agreements in the pharmaceutical market.

Heini is interested in the changes occurring in the pharmaceutical and healthcare industries as well as in the possibilities of Health Economics in assessing the methods and economic resources in the field. Heini’s assets include her state-of-the-art theoretical knowledge in the field of Health Economics, combined with practice- and patient-oriented thinking.


Joel Jukka
Market Access Specialist

Joel Jukka

Market Access Specialist
M.Sc. (Pharmacy), M.Sc. (Natural Science)

+358 50 305 8529 LinkedIn

Joel started working at Medaffcon in December 2015 as a Market Access Specialist. Previously, he has worked for two years in international Market Access tasks (antidepressants and antipsychotics). In addition to this, he has experience in working as a Market Access Consultant and at a pharmacy.

Joel is educated as a Master of Science (Pharmacy) degree, specialised in biopharmaceutics. Moreover, he has a Master of Science (Natural Sciences) degree in applied biotechnology. In the field, Joel is interested in the pricing and reimbursement processes as well as in the related influential parties, which enable the best possible requirements for making the pharmaceutical product available to the patient.


Lotta Koski
Health Economist

Lotta Koski

Health Economist
M.Sc. (Health Economics)

+358 50 431 5869 LinkedIn

Lotta joined Medaffcon in spring 2017. Lotta holds a master’s degree in Health Sciences, Health Economics as her major. In her master`s thesis, Lotta analysed how real-world data can be utilised in the assessment of drug costs. Lotta has worked at Orion during her studies. 

Lotta brings to Medaffcon`s team expertise in Health Economics that she applies in health technology assessments and price and reimbursement processes. 

In the field, Lotta`s special interests are to work for the benefit of patients and how health economic information is utilised in health care decision making. “I believe that knowledge of health economics and the need for health economic information will play an increasingly important role in future health care.” 


Triin Männik
Health Economist

Triin Männik

Health Economist
M.Sc. (Health Economics)

+358 40 768 1525 LinkedIn

Triin joined Medaffcon´s health economic team in April 2015. Triin´s main field of responsibilities are health economic and pharmaceuticals market access related projects, for example, health economic evaluations and price and reimbursement applications. During the consultant career at Medaffcon, Triin has also been an in-house consultant for one pharma company in Market Access Manager role for almost two years. 

Triin has a Master of Science degree majoring Health Economics and a degree as a registered nurse. Triin has previous working experience from the pharmaceutical industry in Market Access function and from an operating theatre in the public sector. 

“It´s great to be involved in the constantly developing field of health care and market access, such as conditional reimbursement, risk-sharing agreements at hospitals, and HTAs, to mention just a few examples. The best thing about my job is to promote the use of cost-effective health care technologies.”


Tatu Sainio
Sr. Health Economist
Access & HE Lead

Tatu Sainio

Sr. Health Economist
Access & HE Lead
M.Sc. (Economics & Health Economics)

+358 44 530 5525 LinkedIn

Tatu joined Medaffcon in the fall of 2016. Tatu holds two Master’s degrees majoring in marketing and health economics. Before joining Medaffcon Tatu worked in the pharmaceutical industry at Boehringer Ingelheim as an Account Manager. At Medaffcon Tatu works mainly with health technology assessments and is the access & health economics team lead. Through his educational and professional background, Tatu has a wide range of expertise in the pharmaceutical industry and understands the needs of each function.

Tatu’s strength is his comprehensive understanding of the pharmaceutical industry and healthcare environment. Tatu is particularly interested in the possibility to turn data into understandable information to support healthcare decision-making. “I love the hype around the utilization of real-world effectiveness and cost-effectiveness data. Now we need steps to include the data as a systematic part of the decision-making process, which allows optimal allocation of resources.”